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G84E missense mutations in HOXB13 are associated with prostate cancer. However, a wide range of risk 
estimates has been reported. Based on case-control studies, reported OR range from 2 to 20, often with 
wide confidence intervals because mutations are rare in the population. To obtain more precise risk 
estimates, we used a kin-cohort study design and modified segregation analysis, using family data on 
11,988 PCa index-cases (4509 consecutive cases, 870 and 6609 cases recruited based on family history 
and young age at diagnosis, respectively) enrolled in the UK Genetic Prostate Cancer Study, who had been 
genotyped for G84E. Among index-cases, 182 carried at least one copy of G84E. PCa incidence was 
assumed to follow a mixed Cox regression model of the form 𝜆(𝑡) = 𝜆0(𝑡)×exp(𝐺 + 𝑃), where G is a fixed 
effect which depends on G84E, 𝑃 ∈ 𝑁(0, 𝜎𝑃
2) a residual polygenic random effect, and 𝜆0(𝑡) is the baseline 
incidence for non-carriers to age t. Using maximum likelihood, after adjusting for ascertainment, we 
estimated the frequency and RR (i.e. penetrance) for G84E under different genetic models, and 𝜎𝑃. 
Preliminary results suggest that under the best fitting model, the data are consistent with a multiplicative 
model where each copy of G84E confers RR for PCa of 2.6 (95%CI 1.7-4.2), and a significant 𝜎𝑃 of 1.8 
(95%CI 1.7-1.9), indicating that family history increases risk above that resulting from being a mutation 
carrier. Ongoing work will evaluate effect-modification of RR and/or 𝜎𝑃 by age, birth cohort, and 
mutation status, and estimate absolute risks for reference family structures. 
 
